MA26730A1 - Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26730A1
MA26730A1 MA25963A MA25963A MA26730A1 MA 26730 A1 MA26730 A1 MA 26730A1 MA 25963 A MA25963 A MA 25963A MA 25963 A MA25963 A MA 25963A MA 26730 A1 MA26730 A1 MA 26730A1
Authority
MA
Morocco
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
antagonist compounds
npy antagonist
Prior art date
Application number
MA25963A
Other languages
English (en)
Inventor
Louis Elliott Richard
Frederick Hank Richard
Hammond Marlys
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26730A1 publication Critical patent/MA26730A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25963A 1999-04-30 2000-04-26 Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant MA26730A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13202999P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
MA26730A1 true MA26730A1 (fr) 2004-12-20

Family

ID=22452122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25963A MA26730A1 (fr) 1999-04-30 2000-04-26 Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (12)

Country Link
US (2) US6355635B1 (fr)
AR (1) AR028824A1 (fr)
AU (1) AU2935200A (fr)
CO (1) CO5170414A1 (fr)
GT (1) GT200000057A (fr)
HN (1) HN2000000041A (fr)
MA (1) MA26730A1 (fr)
PA (1) PA8493701A1 (fr)
PE (1) PE20010118A1 (fr)
TN (1) TNSN00092A1 (fr)
UY (1) UY26130A1 (fr)
WO (1) WO2000066578A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1237875B1 (fr) * 1999-12-16 2005-08-31 Schering Corporation Antagonistes du recepteur y5 au neuropeptide y a imidazoles substituees
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
AU2002351381B2 (en) * 2001-12-17 2007-06-07 Merck & Co., Inc. Method for treating circadian rhythm disruptions
EP1474401A2 (fr) * 2002-02-05 2004-11-10 Novo Nordisk A/S Nouvelles aryl- et heteroarylpiperazines
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2005000217A2 (fr) * 2003-06-06 2005-01-06 Merck & Co., Inc. Polytherapie permettant de traiter la dyslipidemie
WO2005009976A1 (fr) 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl-piperazines et leur utilisation en tant que ligands du recepteur histaminique h3
EP1670468A1 (fr) * 2003-09-26 2006-06-21 Pfizer Products Inc. Utilisation d'un antagoniste du recepteur y5 du npy pour le traitement des troubles du rythme circadien
CA2540197A1 (fr) * 2003-09-26 2005-04-07 Pfizer Products Inc. Traitement des dereglements neurologiques lies a des troubles du sommeil paradoxal avec un antagoniste du recepteur y5 du npy
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005103039A1 (fr) * 2004-04-15 2005-11-03 Neurocrine Biosciences, Inc. 2- (3-aminopyrrolidin-1-yl) pyridines utilisees comme antagonistes du recepteur de l'hormone concentrant la melanine, et compositions et procedes associes
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
JP2008514616A (ja) * 2004-09-24 2008-05-08 メルク エンド カムパニー インコーポレーテッド 肥満の治療のための組合せ療法
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
CA2618646A1 (fr) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
AU2006331656B2 (en) * 2005-12-22 2012-08-09 Icagen, Inc. Calcium channel antagonists
EP2038256A1 (fr) 2006-05-23 2009-03-25 TransTech Pharma, Inc 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine et son utilisation comme medicament
EP2402324A1 (fr) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpipérazinylpyridazines
WO2008033575A2 (fr) * 2006-09-15 2008-03-20 Metabolon, Inc. Procédés d'identification de cheminements biochimiques
BRPI0808789A2 (pt) * 2007-03-16 2014-08-12 Actelion Pharmaceuticals Ltd Compostos e composição farmacêutica de derivados aminopiridina e uso destes
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
EP2280703A1 (fr) * 2008-03-12 2011-02-09 Københavns Universitet (University Of Copenhagen) Utilisation d antagonistes de récepteur npy y5 pour la prévention de l abus de psychostimulants et d opioïdes
CA2750577A1 (fr) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c de type ns5a
HUE029002T2 (en) 2010-12-17 2017-01-30 Mitsubishi Tanabe Pharma Corp Continuous aricyclic compounds
JP5977349B2 (ja) 2012-06-15 2016-08-24 田辺三菱製薬株式会社 芳香族複素環化合物
US10328064B2 (en) * 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
EP4368184A3 (fr) 2019-11-19 2024-07-31 Modag GmbH Nouveaux composés pour le diagnostic, le traitement et la prévention de maladies associées à l'agrégation de l'alpha-synucléine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440774A (en) 1975-03-03 1984-04-03 Merck & Co., Inc. 3-Amino-2-hydroxypropoxyaryl imidazole derivatives
US4853383A (en) 1975-03-03 1989-08-01 Merck & Co., Inc. β-blocking substituted imidazoles
JPH0251150A (ja) * 1988-08-12 1990-02-21 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE59006842D1 (de) * 1990-03-30 1994-09-22 Heumann Pharma Gmbh & Co Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung.
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
AU692977B2 (en) 1994-11-07 1998-06-18 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
EP0759441A3 (fr) * 1995-06-30 1999-06-30 Eli Lilly And Company Procédés de traitement des pathologies associées aux peptides neuropeptide Y
BR9810651A (pt) * 1997-07-03 2000-10-03 Neurogen Corp Certos derivados de diarilimidazol; uma nova classe de ligantes npy especìficos
US6096745A (en) * 1998-03-25 2000-08-01 Bristol-Myers Squibb Co. Imidazolone anorectic agents: III. heteroaryl derivatives

Also Published As

Publication number Publication date
PE20010118A1 (es) 2001-02-03
AR028824A1 (es) 2003-05-28
GT200000057A (es) 2001-10-20
AU2935200A (en) 2000-11-17
US6355635B1 (en) 2002-03-12
US20010039277A1 (en) 2001-11-08
US6514966B2 (en) 2003-02-04
TNSN00092A1 (fr) 2005-11-10
CO5170414A1 (es) 2002-06-27
PA8493701A1 (es) 2002-07-30
WO2000066578A1 (fr) 2000-11-09
HN2000000041A (es) 2001-02-02
UY26130A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
MA26730A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26712A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26740A1 (fr) Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26743A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26680A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2827604B1 (fr) Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
MA26611A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26669A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2794742B1 (fr) Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
DZ3000A1 (fr) Macrolides nouveaux, procédé pour leur préparationet compositions pharmaceutiques les contenant.
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26707A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26501A1 (fr) Derives de quinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26642A1 (fr) Derives de sulfonylbenzene nouveaux, procédé pour leur preparation et compositions pharmaceutiques les contenant.
MA26619A1 (fr) Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26597A1 (fr) Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26631A1 (fr) Composes a fonction bis-aminomethyl-carbonyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26594A1 (fr) Composes nouveaux inhibiteurs de mmp, procede pour leur preparation et compositions pharmaceutiques les contenant